Literature DB >> 3092851

Effect of oral verapamil on glibenclamide stimulated insulin secretion.

C G Semple, C Omile, K D Buchanan, G H Beastall, K R Paterson.   

Abstract

In order to study the effect of the calcium antagonist, verapamil, on glibenclamide stimulated insulin release, nine healthy fasted male volunteers were given 5 mg oral glibenclamide with either 120 mg oral verapamil or placebo in a double-blind crossover manner 1 week apart. Blood was withdrawn at intervals for drug, hormonal and glucose estimations. Concomitant administration of verapamil resulted in higher levels of glibenclamide at each time point (P less than 0.01) suggesting that verapamil interferes with glibenclamide metabolism. However, levels of plasma glucose, C-peptide, insulin and glucagon did not differ between the verapamil and placebo studies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092851      PMCID: PMC1401102          DOI: 10.1111/j.1365-2125.1986.tb05248.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Calcium antagonists and islet function--III. The possible site of action of verapamil.

Authors:  W J Malaisse; A Herchuelz; J Levy; A Sener
Journal:  Biochem Pharmacol       Date:  1977-04-15       Impact factor: 5.858

2.  Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.

Authors:  L M Fuccella; V Tamassia; G Valzelli
Journal:  J Clin Pharmacol New Drugs       Date:  1973 Feb-Mar

3.  Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum.

Authors:  S C Cole; R J Flanagan; A Johnston; D W Holt
Journal:  J Chromatogr       Date:  1981-11-20

4.  Influence of meso-caval shunt surgery on verapamil kinetics, bioavailability and response.

Authors:  M Eichelbaum; M Albrecht; G Kliems; K Schäfer; A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

5.  Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor.

Authors:  L De Marinis; A Barbarino
Journal:  Metabolism       Date:  1980-07       Impact factor: 8.694

6.  Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects.

Authors:  J Kleinbaum; H Shamoon
Journal:  Diabetes Care       Date:  1984 Mar-Apr       Impact factor: 19.112

7.  Determination of oral anti-diabetic agents in human body fluids using high-performance liquid chromatography.

Authors:  H M Hill; J Chamberlain
Journal:  J Chromatogr       Date:  1978-02-11

8.  Beta-adrenoceptor-blocking drugs and blood sugar control in diabetes mellitus.

Authors:  A D Wright; S G Barber; M J Kendall; P H Poole
Journal:  Br Med J       Date:  1979-01-20

9.  Oral verapamil does not affect glucose tolerance in non-diabetics.

Authors:  C G Semple; J A Thomson; G H Beastall; A R Lorimer
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

10.  Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.

Authors:  A Dornhorst; S H Powell; J Pensky
Journal:  Lancet       Date:  1985-01-19       Impact factor: 79.321

View more
  6 in total

1.  Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

Authors:  S W Coppack; A F Lant; C S McIntosh; A V Rodgers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

2.  Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide.

Authors:  Jari J Lilja; Mikko Niemi; Hanna Fredrikson; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2007-01-12       Impact factor: 4.335

3.  Influence of short term verapamil treatment on glucose metabolism in patients with non-insulin dependent diabetes mellitus.

Authors:  M Busch Sørensen; H Sjøstrand; H Sengeløv; M Tiefenthal Thrane; J Juul Holst; J Lyngsøe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.

Authors:  Manthena V S Varma; Renato J Scialis; Jian Lin; Yi-An Bi; Charles J Rotter; Theunis C Goosen; Xin Yang
Journal:  AAPS J       Date:  2014-05-17       Impact factor: 4.009

Review 5.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

6.  Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.

Authors:  Ryuta Asaumi; Kota Toshimoto; Yoshifusa Tobe; Kenta Hashizume; Ken-Ichi Nunoya; Haruo Imawaka; Wooin Lee; Yuichi Sugiyama
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-02-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.